Format

Send to

Choose Destination
J Diabetes Treat. 2017;2017(4). doi: 10.29011/2574.7568.000033. Epub 2017 Dec 19.

Exenatide Prevents Diet-induced Hepatocellular Injury in A CEACAM1-Dependent Mechanism.

Author information

1
Center for Diabetes and Endocrine Research (CeDER), College of Medicine and Life Sciences, University of Toledo, Toledo, OH, USA.
2
Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, USA.
3
Diabetes Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, USA.

Abstract

The Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) promotes insulin sensitivity by inducing insulin clearance and reducing de novo lipogenesis in the liver. Consistently, Cc1-/- mice with null deletion of Ceacam1 gene exhibit hyperinsulinemia and insulin resistance, in addition to steatohepatitis. They also exhibit early pericellular fibrosis. Redelivering Ceacam1 to the liver reverses the altered metabolism and histopathology of Cc1-/- mice. Exenatide, a long-acting glucagon-like peptide-1 receptor agonist, induces Ceacam1 transcription and consequently, reverses impaired insulin clearance and insulin resistance caused by high-fat intake. Additionally, it reverses fat accumulation in the liver. The current studies show that exenatide also restored the activities of alanine transaminase and aspartate aminotransferase, and reversed the inflammatory and oxidative stress response to high-fat diet in wild-type, but not in Cc1-/- mice. Exenatide also prevented diet-induced activation of the TGFβ/Smad2/Smad3 pro-fibrogenic pathways, and normalized the mRNA levels of pro-fibrogenic genes in wild-type, but not in Cc1-/- mice. Together, the data demonstrate that exenatide prevented diet-induced pro-fibrogenesis and hepatocellular injury in a CEACAM1-dependent mechanism.

KEYWORDS:

Fibrosis; Glucagon-Like Peptide-1; Insulin Clearance; Insulin Resistance; Steatohepatitis

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center